Klaricid/Klaricid OD Indications/Uses

Klaricid film-coated tablet: Clarithromycin is indicated for treatment of infections due to susceptible organisms in adults and children 12 years and older. Such infections include: Lower respiratory tract infections (e.g., bronchitis, pneumonia) (see Precautions and Pharmacology: Pharmacodynamics under Actions regarding Sensitivity Testing).
Upper respiratory tract infections (e.g., pharyngitis, sinusitis).
Skin and soft tissue infections (e.g., folliculitis, cellulitis, erysipelas) (see Precautions and Pharmacology: Pharmacodynamics under Actions regarding Sensitivity Testing).
Disseminated or localized mycobacterial infections due to Mycobacterium avium or Mycobacterium intracellulare. Localized infections due to Mycobacterium chelonae, Mycobacterium fortuitum, or Mycobacterium kansasii.
Clarithromycin is indicated for the prevention of disseminated Mycobacterium avium complex infection in HIV-infected patients with CD4 lymphocyte counts less than or equal to 100/mm³.
Clarithromycin in the presence of acid suppression is also indicated for the eradication of H. pylori resulting in decreased recurrence of duodenal ulcer (see Pharmacology: Pharmacodynamics under Actions).
Treatment of odontogenic infections.
Consideration should be given to national official guidance on the appropriate use of antibacterial agents.
Klaricid granules for suspension: Clarithromycin is indicated for treatment of infections due to susceptible organisms in children 6 months to 12 years. Such infections include: Lower respiratory tract infections (e.g., bronchitis, pneumonia) (see Precautions and Pharmacology: Pharmacodynamics under Actions regarding Sensitivity Testing).
Upper respiratory tract infections (e.g., pharyngitis, sinusitis).
Skin and soft tissue infections (e.g., folliculitis, cellulitis, erysipelas) (see Precautions and Pharmacology: Pharmacodynamics under Actions regarding Sensitivity Testing).
Disseminated or localized mycobacterial infections due to Mycobacterium avium or Mycobacterium intracellulare. Localized infections due to Mycobacterium chelonae, Mycobacterium fortuitum, or Mycobacterium kansasii.
Acute otitis media.
Consideration should be given to national official guidance on the appropriate use of antibacterial agents.
Klaricid OD modified-release tablet: Clarithromycin is indicated for treatment of infections due to susceptible organisms in adults and children 12 years and older. Such infections include: Lower respiratory tract infections (e.g., bronchitis, pneumonia) (see Precautions and Pharmacology: Pharmacodynamics under Actions regarding Sensitivity Testing).
Upper respiratory tract infections (e.g., pharyngitis, sinusitis).
Skin and soft tissue infections (e.g., folliculitis, cellulitis, erysipelas) (see Precautions and Pharmacology: Pharmacodynamics under Actions regarding Sensitivity Testing).
Treatment of odontogenic infections.
Consideration should be given to national official guidance on the appropriate use of antibacterial agents.